Alert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 6:00 pm through Wednesday, March 04, 12:00 am (EST), 2026
Ordering can continue through fax and phone.
Contact us
Alert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 6:00 pm through Wednesday, March 04, 12:00 am (EST), 2026
Ordering can continue through fax and phone.
Contact usAlert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 6:00 pm through Wednesday, March 04, 12:00 am (EST), 2026
.Ordering can continue through fax and phone.
Contact usLooks like you're visiting us from {countryName}. You’re currently on the {originCountryName} site. Do you want to switch to a different country site?
Testing {countryName} {originCountryName}
The BD OneFlow™ LST is part of the innovative BD OneFlow™ Solution, a comprehensive set of reagents, setup beads, protocols and assay templates to reproducibly set up the flow cytometer and stain, acquire and analyze patient specimens for immunophenotyping of normal and aberrant cell populations. It is built on the research and validation work of the EuroFlow™ Consortium on the characterization of hematological malignancies for improved accurate diagnosis.1*
The BD OneFlow™ LST is intended for flow cytometric immunophenotyping of normal and aberrant mature lymphocyte populations of B, T and NK cell lineages in peripheral blood, bone marrow and lymph nodes.
Other reagents belonging to the BD OneFlow™ Solution are BD OneFlow™ B-CLPD T1, BD OneFlow™ PCST, BD OneFlow™ PCD.
FEATURES
For BD FACSLyric™ Flow Cytometer users:
For BD FACSCanto™ II Flow Cytometer users:
| Antibody | Fluorochrome | Clone | Target Populations |
|---|---|---|---|
| CD45 | BD Horizon V500-C | 2Dl (anti-HLe-1) | Mature lymphocytes, B-cell precursor |
CD19 | PE-Cy7 | SJ25-C1 | B-cells, and NK-cells by exclusion |
| CD20 | BD Horizon V450 | L27 | B-cells, and NK-cells by exclusion |
| Anti-Lambda | FITC | 1-155-2 | Normal and clonally expanded B cells |
| Anti-Kappa | PE | TB28-2 | Normal and clonally expanded B Cells |
| CD38 | APC-H7 | HB7 | Plasma cells and B-cell precursors, Lymphoid malignancies, NK cells |
| CD3 | APC | SK7 | T cells, B- and NK-cells by exclusion |
| CD4 | BD Horizon™ 450 | SK3 (Leu-3a) | T cell subpopulations |
| CD8 | FITC | SK1 (Leu-2a) | T cell subpopulations |
| CD5 | PerCP-Cy5.5 | L17F12 | T cell subpopulations |
| Anti-TCR-1 | PE-Cy7 | 11F2 | T cell subpopulations |
| CD56 | PE | MY31 (Leu-19) | NK Cells |
The EuroFlow antibody panel article1* has a full description of the utility of the antibodies chosen for the BD OneFlow™ LST.
APPLICATIONS
Laboratory report of a normal bone marrow specimen stained with the 8-color 12-antibody BD OneFlow™ LST single-test reagent acquired on the BD FACSLyric™ Flow Cytometer with BD FACSuite™ Clinical Application v1.4 for the identification of normal and aberrant mature lymphocyte populations of B, T and NK cell lineages.
Laboratory report of an abnormal bone marrow specimen stained with the 8-color 12-antibody BD OneFlow™ LST single-test reagent acquired on the BD FACSLyric™ Flow Cytometer with BD FACSuite™ Clinical Application v1.4 for the identification of normal and aberrant mature lymphocyte populations of B, T and NK cell lineages.
The EuroFlow “LST detected aberrant B-, T-, or NK-cells immunophenotypes in 149/150 (99.4%) of B-CLPD and in 78/83 (94%) of T/NK-CLPD with an overall frequency of 97.4%."1*
Results from the clinical trial study show that the BD OneFlow™ LST in combination with the BD OneFlow™ B-CLPD T1 gave 100% (101 of 101) overall agreement in classifying patients as having CLL (54 of 54 concordant) and in identifying patients with other B cell chronic lymphoproliferative diseases (47 out of 47 concordant) when compared with the EuroFlow system. Furthermore, interpretation of the BD OneFlow™ Solution results was highly concordant to diagnostic truth.
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.